Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Endocrinology

Articles with lock require a GLG News subscription
Posted April 9, 2008
New Data Showed Actos (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
Analysis of: New Data Showed Actos (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes | pharmalive.com
Author: GLG Member Program Contributor
The recent findings regarding pioglitazone in a large, randomized, intravascular cardiac ultrasound study finally begin to show some indication of the expected efficacy for which many physicians chose to use the drug, i.e., to decrease cardiovascular disease or its progression.  From...
Posted April 9, 2008
Taranabant looks promising
Analysis of: Taranabant looks promising | www.taranabant-health.com
Author: GLG Member Program Contributor
Merck's endocannabinoid inverse agonist (CB1R )recently completed a 52 wk trial in which 2000 subjects were randomized to placebo, 2, 4, or 6 mg of taranabant.  Before the trial ended, the 6 mg dosed subjects had to be rerandomized to placebo or 4 mg due to toxicity.  The...
Posted April 8, 2008
Amgen Drug Helps Bones
Analysis of: Amgen Drug Helps Bones | online.wsj.com
Author: GLG Member Program Contributor
the first issue for me to wonder about is the mechanism of action, and what type of drug is it?  Is it a biological or bisphosphonate?  What are potential side effects?  Long or short term.  What are the contra-indications?  Can it be used in children with bone metabolism disorders,...
Posted April 8, 2008
Amgen Drug Helps Bones
Analysis of: Amgen Drug Helps Bones | online.wsj.com
Author: GLG Member Program Contributor
Osteoporosis treatment is becoming highly competitive.  So how competitive is Denosumab's profile?
Posted April 7, 2008
Taranabant looks promising
Analysis of: Taranabant looks promising | www.taranabant-health.com
Author: GLG Member Program Contributor
Although the concept is exciting--an inverse agonist at the cannabinoid-1 (CB-1) receptor to reduce appetite, this medicine has a lot of bad press from rimonabant to overcome.  The major problem with rimonabant was psychopathological reactions in patients.  We do not yet know whether this...
Posted April 7, 2008
Amgen Drug Helps Bones
Analysis of: Amgen Drug Helps Bones | online.wsj.com
Author: GLG Member Program Contributor
We indeed better meds for the treatment of osteoporosis. If it indeed shows fracture reduction besides increased bone density with few side effects it will have a place in the market.The other issue, however, will be the cost and which insurers will cover it now that we have generic fosomax.
Posted April 7, 2008
Taranabant looks promising
Analysis of: Taranabant looks promising | www.taranabant-health.com
Author: GLG Member Program Contributor
The article shows that Taranabant is promising anti-obesity drug that may have better luck with the FDA than Rimonabant. Although the trial results are excellent, the company removed higher doses from future trials! What we should learn from Rimonabant failure and Exenatide success?
Posted April 7, 2008
Phase III Data Showed Taranabant, Merck's Investigational Medicine to Treat Obesity, Led to Statistically Significant Weight Loss
Analysis of: Phase III Data Showed Taranabant, Merck's Investigational Medicine to Treat Obesity, Led to Statistically Significant Weight Loss | pharmalive.com
Author: GLG Member Program Contributor
The market is hungry for a weight loss drug with diabetes benefit. Currently, the FAD has phobia of the SEs with new drugs in this category Failure of Rimonabant was due to wrong direction of Sanofi Aventis in their approach to the FDA Taranabant may have better luck, especially if Merck take...
Posted April 7, 2008
Phase III Data Showed Taranabant, Merck's Investigational Medicine to Treat Obesity, Led to Statistically Significant Weight Loss
Analysis of: Phase III Data Showed Taranabant, Merck's Investigational Medicine to Treat Obesity, Led to Statistically Significant Weight Loss | pharmalive.com
Author: GLG Member Program Contributor
This drug also has a significant side effect profile related to pyschiatric issues. Similar drugs have not come to the market because of this.
Posted April 4, 2008
Phase III Data Showed Taranabant, Merck's Investigational Medicine to Treat Obesity, Led to Statistically Significant Weight Loss
Analysis of: Phase III Data Showed Taranabant, Merck's Investigational Medicine to Treat Obesity, Led to Statistically Significant Weight Loss | pharmalive.com
Author: GLG Member Program Contributor
This article has reported Merck's successful clinical trial to obtain significant efficacy for Taranabant, an investigational medicine to treat Obesity. The news is particularly important for showing a longitudinal effect in the clinical significance for Taranabant, and a prospective market for...
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next41 to 50 of 347

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics